EyeCyte Nets Series A Funding Of $3 Million
Tuesday, June 24, 2008 5:39:00 AM PDT | VentureDeal Staff
ENCINITAS, CA -- Pharmaceutical research company EyeCyte (no web site) announced that it has received $3 million in its first round of institutional venture capital financing.
EyeCyte is a stem/progenitor cell ophthalmology research company developing treatments for retinal disease as discovered by Professor Martin Friedlander.
Pfizer Strategic Investments Group made the investment. The financing will fund the company through 2010 and will drive product development for the company's first clinical target, diabetic retinopathy.
Email Page | Print Page